Viracta Therapeutics, Inc. Common Stock
VIRX
VIRX was delisted on the 3rd of February, 2025.
104 hedge funds and large institutions have $380M invested in Viracta Therapeutics, Inc. Common Stock in 2014 Q3 according to their latest regulatory filings, with 24 funds opening new positions, 37 increasing their positions, 28 reducing their positions, and 22 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
40% more call options, than puts
Call options by funds: $35.7M | Put options by funds: $25.5M
32% more repeat investments, than reductions
Existing positions increased: 37 | Existing positions reduced: 28
20% more capital invested
Capital invested by funds: $316M → $380M (+$63.8M)
2% more funds holding
Funds holding: 102 → 104 (+2)
9% more first-time investments, than exits
New positions opened: 24 | Existing positions closed: 22
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
+$21.9M |
| 2 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$18.8M |
| 3 |
LCP
Lamond Capital Partners
San Francisco,
California
|
+$9.1M |
| 4 |
EAM
Eagle Asset Management
St Petersburg,
Florida
|
+$8.11M |
| 5 |
Fidelity Investments
Boston,
Massachusetts
|
+$6.21M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$6.74M |
| 2 |
FCM
Farallon Capital Management
San Francisco,
California
|
-$4.37M |
| 3 |
Franklin Resources
San Mateo,
California
|
-$3.73M |
| 4 |
PCM
Palisade Capital Management
Fort Lee,
New Jersey
|
-$3.29M |
| 5 |
Point72 Asset Management
Stamford,
Connecticut
|
-$3.06M |
VIRX Hedge Fund Activity: Q3 2014 in Review
104 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Viracta Therapeutics, Inc. Common Stock (VIRX) for Q3 2014, worth a combined $380M — up 20% from $316M a quarter earlier.
Buyers outnumbered sellers: 24 funds opened new VIRX positions and 22 closed out — a net gain of 2 holders — while 37 added to existing stakes and 28 trimmed.
The largest buyer was Citadel Advisors, adding an estimated $21.9M. The largest seller was NEA Management Company, cutting an estimated $6.74M.
- 104 institutional investors held Viracta Therapeutics, Inc. Common Stock (VIRX) as of Q3 2014, up from 102 in Q2 2014.
- Funds reported $380M of Viracta Therapeutics, Inc. Common Stock stock for Q3 2014, up 20% quarter-over-quarter.
- 24 funds opened new Viracta Therapeutics, Inc. Common Stock positions in Q3 2014 and 22 closed out, a net change of +2 holders.
- The largest Viracta Therapeutics, Inc. Common Stock buyer in Q3 2014 was Citadel Advisors, an estimated $21.9M added.
- The largest Viracta Therapeutics, Inc. Common Stock seller in Q3 2014 was NEA Management Company, an estimated $6.74M sold.
Based on aggregated 13F filings for Q3 2014.